These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 22947426

  • 1. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
    Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME, 1263-301 Clinical Study Group.
    Am J Transplant; 2012 Nov; 12(11):3021-30. PubMed ID: 22947426
    [Abstract] [Full Text] [Related]

  • 2. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S.
    Clin Infect Dis; 2019 Apr 08; 68(8):1255-1264. PubMed ID: 30329038
    [Abstract] [Full Text] [Related]

  • 3. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
    Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M.
    Blood; 2008 Jun 01; 111(11):5403-10. PubMed ID: 18285548
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 01; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 5. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
    Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M, Maribavir 1263-300 Clinical Study Group.
    Lancet Infect Dis; 2011 Apr 01; 11(4):284-92. PubMed ID: 21414843
    [Abstract] [Full Text] [Related]

  • 6. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR.
    World J Gastroenterol; 2008 Aug 21; 14(31):4849-60. PubMed ID: 18756591
    [Abstract] [Full Text] [Related]

  • 7. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
    Trofe J, Pote L, Wade E, Blumberg E, Bloom RD.
    Ann Pharmacother; 2008 Oct 21; 42(10):1447-57. PubMed ID: 18698013
    [Abstract] [Full Text] [Related]

  • 8. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.
    Drugs R D; 2007 Oct 21; 8(3):188-92. PubMed ID: 17472414
    [Abstract] [Full Text] [Related]

  • 9. In vitro studies of the impact of maribavir on CMV-specific cellular immune responses.
    Stachel D, Stevens-Ayers T, Boeckh M.
    J Clin Virol; 2016 Feb 21; 75():53-9. PubMed ID: 26780109
    [Abstract] [Full Text] [Related]

  • 10. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S, Faulds D.
    Drugs; 1998 Jul 21; 56(1):115-46. PubMed ID: 9664203
    [Abstract] [Full Text] [Related]

  • 11. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
    Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T.
    Ann Intern Med; 1994 Mar 01; 120(5):375-81. PubMed ID: 8304654
    [Abstract] [Full Text] [Related]

  • 12. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.
    Transplantation; 1998 Dec 27; 66(12):1682-8. PubMed ID: 9884259
    [Abstract] [Full Text] [Related]

  • 13. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH.
    Transplantation; 1998 Dec 27; 66(12):1780-6. PubMed ID: 9884276
    [Abstract] [Full Text] [Related]

  • 14. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J, Cordonnier C, Jaksch P, Poiré X, Uknis M, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S.
    N Engl J Med; 2019 Sep 19; 381(12):1136-1147. PubMed ID: 31532960
    [Abstract] [Full Text] [Related]

  • 15. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
    Turgeon N, Fishman JA, Doran M, Basgoz N, Tolkoff-Rubin NE, Cosimi AB, Rubin RH.
    Transpl Infect Dis; 2000 Mar 19; 2(1):2-10. PubMed ID: 11429003
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
    Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, Valganciclovir Solid Organ Transplant Study Group.
    Am J Transplant; 2004 Apr 19; 4(4):611-20. PubMed ID: 15023154
    [Abstract] [Full Text] [Related]

  • 17. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.
    Transplantation; 1997 Jul 15; 64(1):66-73. PubMed ID: 9233703
    [Abstract] [Full Text] [Related]

  • 18. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA.
    Biol Blood Marrow Transplant; 2001 Jul 15; 7(6):343-51. PubMed ID: 11464977
    [Abstract] [Full Text] [Related]

  • 19. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB, Phadke VK, Pouch SM, Mehta AK, Karadkhele G, Larsen CP, Woodworth MH.
    Clin Transplant; 2024 Oct 15; 38(10):e15480. PubMed ID: 39427300
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
    Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR.
    Transplantation; 2000 Sep 15; 70(5):717-22. PubMed ID: 11003347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.